Stockholm3 has been mentioned as a biomarker test in the revised 2023 American Urological Association (AUA) guidelines for early detection of prostate cancer. The AUA guidelines cite a publication (Grönberg et al. 2015, Lancet Oncology1) which has shown that Stockholm3 has a higher predictive accuracy compared to PSA alone, with the…
The 38th annual European Association of Urology (EAU) meeting was held March 10-13, 2023 in Milan, Italy. More sophisticated risk adapted strategies was a focus area, including seven abstracts evaluating Stockholm3 performance in populations across Europe. For the third year in a row a Stockholm3 study was awarded and highlighted on the…
Seven scientific abstracts, one thematic session and one plenary session related to Stockholm3 have been accepted for presentation at the upcoming 38th European Association of Urology (EAU) meeting that will be held March-10-13 in Milan, Italy. The accepted presentations, outlined below, cover topics such as validation of Stockholm3 in…
Groves Medical Group has started offering Stockholm3 for prostate cancer testing. This is the first UK clinic that uses Stockholm3.
Stockholm3 will be offered to men aged 45 to 74 in the South-West London area. The blood samples will be taken at the Groves Medical Centre in New Malden, London and the test analysis will be performed by…
A study comparing Stockholm3 with the Rotterdam Prostate Cancer Risk Calculator (RPCRC) has been published in European Urology Focus (1). RPCRC is a prostate cancer risk calculator that is recommended in the European Association of Urology guidelines. Stockholm3 showed superior performance and a positive clinical benefit whereas the…
A3P Biomedical has appointed Andreas Hoel as VP Marketing & Sales. Andreas Hoel brings more than 20 years´ experience from marketing and sales positions in the life science, diagnostics and medical device industries, most recently at Thermo Fisher in the UK. He joins A3P today and reports to CEO David Rosén.
“I am very pleased…
Zürich University Hospital has started using Stockholm3 for prostate cancer testing. This is the first clinic in Switzerland that uses Stockholm3.
Stockholm3 will be used for men aged 45 to 75 and offered to men in Switzerland. The blood tests will be taken at the Zürich University Hospital and the test analysis will be performed by…
As part of the EU Cancer Screening Scheme to be put forward under Europe’s Beating Cancer Plan, the European Commission has presented a new approach to support Member States in increasing the uptake of cancer screening. One key element of the recommendation is to extend organized screening programs to include prostate cancer. The…
A3P Biomedical has formed a Scientific Advisory Board (SAB), comprised of scientific and clinical leaders in urology and oncology, and chaired by professor Per-Anders Abrahamsson, former Secretary General of the European Association of Urology (EAU). The SAB will provide expertise and counsel to management in strengthening the clinical…
NICE, the UK National Institute for Health and Care Excellence, has published a Medtech Innovation Briefing (MIB) on Stockholm3, where experts state that Stockholm3 has the potential of improving accuracy in prostate cancer diagnostics. The MIB report is not a recommendation, but generally seen as a first step towards diagnostic guidance…
In February 2022, a proposal for revised Swedish national guidelines for prostate cancer was presented and submitted for consultation. The proposal has now been adopted and the group of experts concluded that there is good evidence that Stockholm3 can select men with PSA above a certain level for further investigation and reduce the…
Associate Professor Tobias Nordström is awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". He receives the award for the study STHLM3-MRI, which shows that Stockholm3, combined with magnetic camera examination (MRI), reduces the number of unnecessary biopsies by 76 percent in a general…
A3P Biomedical and Unilabs have initiated a partnership for Stockholm3, A3P Biomedical's blood test for early detection of aggressive prostate cancer. Screening by Stockholm3 is requested by healthcare providers throughout Sweden. The fact that Unilabs now includes Stockholm3 in its catalogue of products will make it possible for…
Region Värmland was the first Swedish region to introduce organized prostate cancer screening in 2015. The program includes men in the age category 50-75 years. The region has now decided to include testing with Stockholm3, a blood test for early detection of aggressive prostate cancer.
"We are very proud and happy to be the first…
At the NUF – Nordisk Urologisk Förening – congress in Helsinki tomorrow a new study that validates the use of Stockholm3 in Finland will be presented. The results of the study show that by using Stockholm3 instead of PSA, the number of men undergoing MRI and/or biopsies could be reduced. The study also shows that the medical…
A3P Biomedical has appointed Anders Martin-Löf as Chief Financial Officer (CFO). Anders Martin-Löf brings more than 20 years’ experience from the life science industry, including CFO positions at Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. He will take up his new position at A3P Biomedical in August and report to…
A3P Biomedical AB (publ) (“A3P Biomedical” or the “Company”), a Swedish diagnostic company that specializes in advanced prostate cancer diagnostics, has successfully completed a private placement of shares (the “Private Placement”) of SEK 400 million to Stena Sessan AB, TomEqt Private AB (1), Flerie Invest AB, The Foundation…
A new clinical validation study in the Värmland Region has been published in European Urology Open Science (1). The results of the study show that Stockholm3 leads to better prostate cancer diagnostics with a reduced number of examinations and lower resource consumption than current Swedish guidelines and can pave the way for future…
On 16 February the revised national prostate cancer guidelines were announced. The revised guidelines state “that there is solid evidence that Stockholm3 can select men with PSA above a certain level for further investigation and, at the same time, reduce the proportion of men who need to undergo magnetic camera examination”. The…
60 percent reduction of MRI (Magnetic resonance imaging) procedures 39 percent reduction of overdiagnostics Cost effective for population-based screening A3P Biomedical AB today announced that a cost-utility analysis based on the STHLM3 MRI trial was published in European Urology (1). The analysis concluded that a Stockholm3 based…
Professor Henrik Grönberg is awarded the Swedish Cancer Foundation’s Cancer Researcher of the Year 2022 for his research that enables early detection of prostate cancer. Henrik Grönberg’s research has led to the test Stockholm3. The Cancer Foundation’s research committee, chaired by former chairman of the Nobel Committee, Klas…
Stockholm3 in combination with MRI enables implementation of population-based screening of prostate cancer The combination decreases unnecessary biopsies by 74 percent STOCKHOLM, August 13, 2021. A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published…
An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69 percent compared to…
STOCKHOLM, June 18, 2021. A3P Biomedical appoints David Rosén as new CEO to lead the commercial expansion of the company’s novel Stockholm3 test for early detection of prostate cancer. David brings more than 20 years’ experience from the medical device industry, including senior international positions at Getinge and Cantel…
STOCKHOLM, March 19, 2021. A3P Biomedical announced today that an independent and peer reviewed study showed health economic benefits using Stockholm3 versus PSA in a screening by invitation setting for prostate cancer. The results from the study demonstrated that Stockholm3 reduced unnecessary biopsies and was cost-effective compared to…
STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion. “In order to realize A3P Biomedical’s growth opportunities, we are building a…
A3P Biomedical announced today that it has raised SEK 110 million in growth capital from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test. Near-term, A3P will focus on accelerating the Nordic launch, as well as preparing commercialization in Europe and North…
A3P Biomedical announced today that a real-life study including 4,784 men has been carried out by Stavanger University Hospital showing that the company’s blood-based Stockholm3 test leads to a 28 percent reduction in prostate cancer work-up, an increase in identification of clinically significant cancers by 55 percent and reduction of…
A3P Biomedical announced today that while continuing the fight against prostate cancer, providing the unique blood-based prostate cancer test Stockholm3, the company is committed to supporting government efforts in responding to covid-19. A3P Biomedical announced today the company will provide resources to support government efforts in…
